Tryp Therapeutics is a pharmaceutical company focused on identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs.

    Learn more

World Class Management

Cohesive, commercially-oriented management team and board with significant overlapping large pharma and emerging pharma experience

Capital Markets

Experience

Big Pharma

Experience

Drug Approvals

Achieved

Profitable Medical Companies

Operated

Pipeline

Developing two unique chemical entities with demonstrable clinical signals

Pipeline

Near-term Phase 2 ready oncology asset – leveraging extensive body of clinical research and familiarity of key opinion leaders (“KOL”) to efficiently expedite development, both in terms of cost and time

Developing psilocybin-based therapeutics for neuropsychiatric indications and will seek regulatory approval pursuant U.S. FDA regulatory pathway

Unmet Medical Needs

Developing therapeutics for diseases with no effective first-line treatments, no competition, translates to pricing power with insurance companies

Near Term Monetization

Developing product candidates through Phase 2 clinical development, then monetize through transaction with big biotech / large pharma

Abbreviated Clinical Path

Leveraging existing clinical data, accelerated clinical development due to smaller, shorter, open-label clinical trials

Latest News

November 16, 2020

Tryp Appoints Dr. Jim Gilligan, PhD, MBIS, as President and Chief Scientific Officer
Read More

September 6, 2020

Tryp Therapeutics Announces Formation of Psilocybin Scientific Advisory Board
Read More

Subscribe to receive updates on the company